Wen Jess Li, Yunfei Wang, Xiaozhuo Liu, Shan Wu, Moyi Wang, Steven G Turowski, Joseph A Spernyak, Amanda Tracz, Ahmed M Abdelaal, Kasireddy Sudarshan, Igor Puzanov, Gurkamal Chatta, Andrea L Kasinski, Dean G Tang
Prostate cancer (PCa) remains a common cancer with high mortality in men due to its heterogeneity and the emergence of drug resistance. A critical factor contributing to its lethality is the presence of prostate cancer stem cells (PCSCs), which can self-renew, long-term propagate tumors, and mediate treatment resistance. MicroRNA-34a (miR-34a) has shown promise as an anti-PCSC therapeutic by targeting critical molecules involved in cancer stem cell (CSC) survival and functions. Despite extensive efforts, the development of miR-34a therapeutics still faces challenges, including non-specific delivery and delivery-associated toxicity...
February 9, 2024: International Journal of Molecular Sciences